Hemant Kumar Pandey, Kaushal Kumar Singh, Birendra Kumar Roy and Suruchi Kumari
The pharmacokinetic study of diminazene aceturate (DMZ) was carried out in two separate groups of 4 e ach clinically healthy female Murrah buffalo calves aft er single dose i.v. (8 mg/kg) and i.m. (16 mg/kg) administrat ion. The mean free peak serum concentration of DMZ (CS max ) after i.v. (26.28±0.67μ g/ml) and i.m. (8.41±2.43 μ g/ml) a dmin- istrations were obtained at t max of 5 and 30 min respectively. The DMZ serum concentrations time data were best fi tted to the two compartment open model. The calculated s erum half life (t ½ β ) values of DMZ were 15.099±2.504 and 14.225±2.682 h after i.v. and i.m. administration r espec- tively. The mean values of total body clearance rat e of DMZ (ClB) after i.m. (3.785±1.119 ml/kg/min) was signif icantly higher (P<0.05) as compared with the i.v. (0.537±0. 063 ml/kg/min). DMZ was highly bound (77.14 to 94.40%) to buffalo calf plasma protein and its penetration int o erythro- cytes increased with increasing concentrations in b lood (7.60 to 33.00μ g/ml). Based on pharmacokinetic profiles, the satisfactory dosage regimens of diminazene aceturat e in buffalo calves were derived (2 mg/kg, i.v. and 12mg /kg, i.m). In case of emergent disease conditions to ens ure high DMZ serum concentrations, i.v. route may be preferr ed over i.m. route.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 